We are thrilled to meet you at the ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE 2024 conference.

The ANIMAL HEALTH, NUTRITION AND TECHNOLOGY INNOVATION EUROPE 2024 conference is taking place from March 4-6, 2024 in the vibrant city of London, UK!

🌐 This event promises to be a hub of groundbreaking discussions and innovations in the realm of animal health, nutrition, and technology. Join us as we explore the latest advancements, share insights, and foster collaboration among esteemed professionals in the field.

📆 Save the Dates:
🗓️ March 4-6, 2024
📍 London, UK

We look forward to meeting you there!

https://www.animalhealthevent.com/events/animal-health-europe

We’re delighted to be supporting the Life Sciences Summit 2024: True science, real change. Join us, 11-12 March in Wellington.

The Life Sciences Summit 2024 will showcase

  • Global thought leadership and insights.

  • Networking with all parts of the ecosystem including government, companies, universities, research institutes, the investment community and students.

  • Roundtables led by industry experts.

  • Showcasing current research, new innovation and commercialisation opportunities.

Our two-day programme features keynote presentations, panel discussions, roundtables and more.

True science, real change!

https://lifesciencessummit.co.nz

VCRN BECOMES THE INVETUS CLINICAL NETWORK

Invetus offers research services to the animal health industry, in any species, at any level of rigour and in any disease state. The Veterinary Clinical Research Network (VCRN) has been part of our offering since we first started Invetus in December 2016. VCRN was a stand-alone division focusing on companion animals in a clinical setting and allowed sponsors to work with pets through research-trained veterinary  hospitals and in owners' homes.

Counting ticks

Counting ticks

Beagle eye check

Beagle eye check

Invetus is constantly seeking to adapt our business model to respond to the many and varied forces in the market. We are seeing restructuring and mergers amongst some of our global customers,  as well as growth in the numbers of pets and spending on veterinary care in many countries. The ongoing uncertainty around living with COVID-19 has also affected all parts of our work, so we need to be focussed and nimble.

It has become clear that there are efficiencies in operating our business units in a more integrated and collaborative way. As a result,  Invetus has decided to  consolidate a number of support functions to allow The Clinical Network to focus on clinical research. These changes will reduce replication of functions at multiple sites and  build excellence by adapting the best practice from across the business.  It will also give us an opportunity to further develop the quality of clinical research, to move to digital data capture and to invest in and strengthen our key capability, the clinical network. 

The network will be known as The Invetus Clinical Network (ICN), reflecting the increased integration and alignment  with the all the companion animal services within  Invetus. 

The ICN offers a unique service to animal health companies. Working in general or specialist veterinary hospitals, or directly in owners' homes, ICN is able to conduct pre- or post-marketing field studies with veterinary medicines, procedures, equipment or feeds . Dr Lisa Wade continues to lead the ICN, and if you wish to discuss your clinical research needs please contact her below.

COVID-19: updated 23 April 2020

Invetus remains operational in both Australia and New Zealand.

As of today, we know of no staff with the virus, nor any close contacts with the virus.

Carly, one of our clinical monitors, ready for a “contactless” study visit with a domestic cat.

Carly, one of our clinical monitors, ready for a “contactless” study visit with a domestic cat.

The Level 4 restrictions in NZ are set to be relaxed over coming weeks, which will make life easier for our people there. Work has continued as animal research was exempt from the restrictions due to the animal welfare component.

As outlined previously, we continue to take a conservative approach to work practices in both places, with PPE including masks as appropriate, separate teams of workers to reduce time spent together, and recording of contacts should tracing be required.

Our focus now is expanding from continuing currently contracted work, to ensuring we have projects for later in 2020 and into 2021.

 If you are thinking about your research needs once the COVID-19 lockdown period eases, please get in touch now – we would love to discuss your research needs and develop a plan for later in the year.


 If you have any questions or concerns, please contact Dr Maurice Webster, Managing Director.

COVID-19: UPDATED 30th MARCH, 2020

Invetus remains operational. As far as possible, all studies continue. In a couple of cases sponsors have suspended studies, or delayed start dates, otherwise work proceeds with the additional measures described below.

As of today, we know of no staff with the virus. We have 2 who have completed self-isolation after returning from holidays, and two currently in self-isolation after contact with a confirmed case. 

We are operating in NZ under the Level 4 restrictions across the whole country, and have been registered with the Ministry of Primary Industry as an “essential service.” This means we can continue our work there, with appropriate safeguards and records in place.  

We are adopting a similar approach for our Australian operations, in order to keep consistency across the business, and to be well prepared if restrictions increase in Australia.

We have convened a Crisis Management Team, which meets early each day to review changes/issues, and make decisions if required..

Actions we have taken with Sponsors

·      Invetus conducted a COVID-19 risk analysis for all projects to ensure that we can initiate and complete studies while keeping staff safe. We applied 4 tests to each Study:

o   Is it legal to conduct the Study under current COVID-19 containment regulations?

o   Can we conduct the study with appropriate safety and social distancing precautions?

o   Are there ways to change the work so it can continue?

o   Do we have enough redundancy to provide acceptable assurances to Sponsors that the Study can be completed?

With the agreement of Sponsors, we have paused some projects which required interaction with Veterinary clinics and/or pet owners, as either the clinics or the owners have decided not to continue. We hope that we can resume these when the situation eases.

Other projects continue, and in some cases we have revised the protocol (with Sponsor approval) to include new processes to keep staff safe.

Actions we have taken with staff:

Where possible, staff are working from home, and have the technology to do that.

For research work and animal welfare activities which cannot be conducted from home, we have adopted a “buddy” system at each site:

  • Staff have been organised into small teams (2-3people), and are assigned separate work tasks, to reduce close contact time.

  • Close contact is up to 15 min face to face, or up to 2 hours in the same room – we are seeking to minimise close contact for all staff.

  • Teams are usually composed of a senior veterinarian or scientist, together with a technician or veterinary nurse.

  • We are requiring all staff to keep a log of all work and personal close contacts, both for traceability should it be required, and to develop an awareness of close contact.

  • We expect staff to minimise or eliminate close contact other than with family and assigned work Teams. In NZ this is required by law.

  • We have sanitiser at all workplaces as well as soap and water and are using protective equipment when we can get it. We have made our own fabric face masks for use in low risk environments to stop staff touching their faces and to increase cough hygiene.

  • All meetings are conducted electronically.

We are privileged to be able to continue working, as we are an essential service. We accept this carries responsibility and are working to safeguard our staff and our business. We are preparing for more difficult business conditions, and are taking advantage of all State & Commonwealth initiatives, in both Australia & NZ, to support small business. It seems unlikely that we will get through this without some pain, like so many others.

If you have any questions or concerns, please contact Dr Maurice Webster, Managing Director.